Conestat alfa

N/A

Report date: 2022/02/11 11:30:35

Base Information

Drug NameConestat alfa
Drug Alias Name考奈司他αHuman C1 esterase inhibitorRecombinant human C1 esterase inhibitorConestat αConestat alpha +[10] 
ClassificationBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionComplement C1 inhibitorsComplement C1s inhibitors
TargetsComplement C1Complement C1s
Therapy Area/IndicationsRejection of renal transplantationCoronavirus Disease 2019 (COVID-19)Graft Rejection +[10] 
Global Approved IndicationsAngioedemas, Hereditary
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2010/10/28
Country/TerritoryCzechiaBulgariaCanada +[17] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesPharming Group Nv
China Registration ClassN/A

Develop Information

Active CompaniesNewbridge PharmaceuticalsSanofiPharming Technologies Bv +[6] 
Inactive CompaniesUniversity Of Wisconsin-Madison
Active IndicationsCoronavirus Disease 2019 (COVID-19)Angioedemas, HereditaryAngioedema +[5] 
Inactive IndicationsRejection of renal transplantationGraft RejectionGenetic Diseases, Inborn +[5] 

Other Information

ATC CodeB06AC04
Related LinksWikipediaDrugBank